Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).
The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...
Malfunctioning glucose trackers made by Abbott Diabetes Care have been linked to more than 700 severe adverse events and seven potential deaths, the Food and Drug Administration (FDA) and Abbott said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback